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Abstract
Due to the overwhelming burden of colorectal cancer 
(CRC), great effort has been placed on identifying genetic 
mutations that contribute to disease development and 
progression. One of the most studied polymorphisms that 
could potentially increase susceptibility to CRC involves the 
nucleotide-binding and oligomerization-domain containing 
2 (NOD2 ) gene. There is growing evidence that the 
biological activity of NOD2 is far greater than previously 
thought and a link with intestinal microbiota and mucosal 
immunity is increasingly sought after. In fact, microbial 
composition may be an important contributor not only 
to inflammatory bowel diseases (IBD) but also to CRC. 
Recent studies have showed that deficient NOD2 function 
confers a communicable risk of colitis and CRC. Despite 
the evidence from experimental models, population-based 
studies that tried to link certain NOD2 polymorphisms and 
an increase in CRC risk have been described as conflicting. 
Significant geographic discrepancies in the frequency 
of such polymorphisms and different interpretations of 
the results may have limited the conclusions of those 
studies. Since being first associated to IBD and CRC, our 
understanding of the role of this gene has come a long 
way, and it is tempting to postulate that it may contribute 
to identify individuals with susceptible genetic background 
that may benefit from early CRC screening programs or 
in predicting response to current therapeutic tools. The 
aim of this review is to clarify the status quo of NOD2 
mutations as genetic risk factors to chronic inflammation 
and ultimately to CRC. The use of NOD2 as a predictor of 
certain phenotypic characteristics of the disease will be 
analyzed as well. 
Key words: Colorectal cancer; Fecal microbiota; Cancer 
susceptibility; Intestinal inflammation; Nucleotide-binding 
and oligomerization-domain containing 2 mutations
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Core tip: Recently, data from animal models showed that 
nucleotide-binding and oligomerization-domain containing 
2 (NOD2) deficiency leads to dysbiosis and to an increased 
risk of colitis and colitis-associated colorectal cancer 
(CRC). Furthermore, it is now known that this receptor 
has a much more expanded role than previously thought. 
Concerning population-based studies, and despite initial 
inconsistencies, recent data points to an important role for 
NOD2 mutations in CRC susceptibility. Identifying carriers 
of such polymorphisms may allow them to be included in 
stricter CRC surveillance programs. A link between NOD2 
mutation carriage and response to different chemotherapy 
regimens is also a promising field of research.
Branquinho D, Freire P, Sofia C. NOD2 mutations and colorectal 
cancer - Where do we stand? World J Gastrointest Surg 2016; 
8(4): 284-293  Available from: URL: http://www.wjgnet.
com/1948-9366/full/v8/i4/284.htm  DOI: http://dx.doi.org/10.4240/
wjgs.v8.i4.284
INTRODUCTION
Despite several advances in the diagnosis and treatment 
of colorectal cancer (CRC), it continues to be one of the 
most significant causes of morbidity and cancer-related 
deaths[1]. Apart from familial syndromes that account 
for 5%-10% of CRC cases[2], this disease is considered 
to have a multifactorial etiology and therefore predicting 
individual risk has been problematic, as there are many 
genetic polymorphisms with probably modest individual 
effect[3]. Due to its proven role as a genetic predisposing 
factor for chronic inflammation, most notably in Crohn’s 
disease (CD)[4], nucleotide-binding and oligomerization-
domain containing 2 (NOD2) mutations have been 
suggested to have a similar role in CRC. This assumption 
derives from the fact that several gastrointestinal cancers 
are strongly linked to chronic inflammatory conditions. 
The risk for malignancy may even increase according to 
the degree of underlying inflammation, as is the case 
for long-standing ulcerative colitis[5] and Helicobacter 
pylori (H. pylori)-induced chronic gastritis. One plausible 
hypothesis is that pro-inflammatory stimulus may lead to 
continuous cell proliferation, angiogenesis and eventually 
DNA damage[6]. If the association between chronic 
inflammation and cancer is based on solid experimental 
and epidemiological data, what remains to be fully 
understood is how do NOD2 mutations lead to chronic 
inflammation? 
The NOD2 protein plays an important role in innate 
immunity by recognizing bacterial lipopolysaccharides 
and activating the nuclear factor-kappaB. The mutant 
alleles for NOD2 gene are thought to cause loss of 
function - deficient recognition, impaired clearance and 
proliferation of bacterial pathogens that lead to increased 
pro-inflammatory cytokines and subsequently to chronic 
inflammation[7]. Recently, the role of NOD2 has been 
analyzed under a different light, as it seems to take a 
central place in the intricate balance between protection 
of the intestinal mucosa under physiological settings and 
the production of pro-inflammatory cytokines in chronic 
inflammatory conditions. Any shift, either gain or loss of 
function for NOD2, elicits a disturbance in the immune 
system that may lead to inflammation[8]. 
Another promising approach to understanding the 
pathogenesis of these diseases is the modulation of 
intestinal microbiota. Formerly considered a passive 
element in the homeostasis of the intestinal mucosa, 
the microbiota is nowadays considered as essential for 
epithelial differentiation and in maintaining a protective 
environment[9]. To that end, commensal bacteria and 
NOD2 interact in a feedback-like mechanism - NOD2 
keeps bacterial proliferation in a steady, controlled 
state and the microbiota intervene in controlling NOD2 
expression[10]. Animal models with high risk genotype 
for colitis and CRC show less severe or even absent 
inflammation and fewer cases of adenomas if raised in 
selected bacterial or germ-free conditions[11], suggesting 
that changes in microbial species affect colitis and CRC 
development. 
From 2004 to 2010, several population-based studies 
tried to find an increased risk for CRC in NOD2 polymor-
phism carriers. The most studied mutations have been 
two missense mutations - R702W (rs2066844 C/T) and 
G908R (rs2066845 C/G), and a frameshift mutation 
- 3020insC (rs2066847 insC). The frequency of these 
polymorphisms differs greatly between populations, 
being much less common in Asian cohorts[12]. Even 
among Caucasian populations, there is significant genetic 
heterogeneity that may have limited the findings of 
such studies. Furthermore, the source of controls and 
the type of methodology used are also potential bias. 
Another relevant finding is that individual polymorphisms 
may increase the risk of CRC only in selected groups 
(e.g., German individuals under 45-year-old carrying 
R702W polymorphism[13]). These promising studies may 
ultimately lead to identifying individuals with susceptible 
genetic background, other than those with well-known 
familial syndromes, therefore benefitting from early 
diagnostic screening. 
In order to find recent publications (2004 to present) 
on NOD2 mutations and CRC susceptibility, an extensive 
literature search was performed using PubMed and 
MEDLINE. The key search terms used were NOD2/
caspase recruitment domain 15 (CARD15) mutations, 
CRC genetics, microbiota, mucosal immunity and chronic 
inflammation, either alone or in combination. All articles 
identified were English-language, full-text papers. We 
also searched the reference lists of identified articles for 
further relevant papers.
THE EXPANDING NOD2 ROLE
In order to protect the epithelium of the gastrointestinal 
tract, the largest surface in our body exposed to 
external environment, a number of obstacles within 
the mucosa are disposed to prevent the spread of 
pathogenic organisms. Besides mechanical barriers 
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such as the mucus layers, the innate immune system is 
probably the first mechanism to act against deleterious 
microorganisms, and once triggered it becomes activated 
within minutes[14]. This almost immediate response is 
due to pathogen recognition receptors (PRRs). One of 
the most prominent families of PRR includes Nod-like 
receptors (NLRs) that recognize bacterial wall component 
peptidoglycan. Certainly the most researched member 
of this family is NOD2, expressed in dendritic cells, 
leukocytes and epithelial cells of the gastrointestinal tract, 
especially after inflammatory stimuli[15]. Paneth cells 
are secretory epithelial cells found in small bowel crypts 
that express significant levels of NOD2. The structural 
features of NLRs include a central nucleotide-binding 
oligomerization domain, a variable N-terminal protein-
protein interaction domain, defined by the CARD, and 
a C-terminal leucine-rich repeat that senses pathogen-
associated molecular patterns[8]. After activation, 
recruitment of a serine threonine kinase called RIP2 
occurs, which leads to the enrollment of the NF-κB 
signaling pathway, leading to the transcription of immune 
response genes[16]. 
Along with this traditional role, NOD2 plays a part 
in the induction of autophagy as well. This process 
leads to the destruction of damaged proteins and orga-
nelles which has paramount importance not only in 
recycling biomolecules but also in eliciting anti-microbial 
properties[17]. Growing evidence has shown that NOD2 
may be also a relevant player in CD4+ T cell function 
and in generating a Th1 response. This leads to the 
production of IFN-γ by T cells. In addition to detecting 
bacterial pathogens, NOD2 has shown a different role 
in host defense. According to in vitro studies, NOD2-
deficient animals showed an increased susceptibility 
to several viral infections[18]. The response to certain 
parasite infections may be compromised as well, due to 
a reduced production of IFN-γ[16,19]. In NOD2-/- animals, 
through stimulation of Th1-associated cytokines, an 
increase in mucosal permeability and low-grade chronic 
inflammation occurs[20].
The aforementioned evidence places NOD2 in the 
center of the immune system, quite distant from its first 
described role as a “simple” pathogen sensor. But the 
essential question remains: How do NOD2 mutations 
predispose to CD and do they have a role in cancer 
development? 
Although our understanding of these complex inter-
actions has improved in recent years, we still have no 
solid evidence to prove that polymorphisms in NOD2 
actually lead to the production of a stable protein. 
Currently, there are at least two possible ways in which 
NOD2 mutations can lead to chronic inflammation and 
CD. The first is related with the basic function of NOD2 as 
a positive regulator for innate response. We can assume 
that if there is no efficient NOD2 activation during early 
phases of pathogen exposure, bacteria will proliferate and 
ultimately lead to chronic inflammation. An alternative 
explanation involves the deficient activation of NOD2 as 
well, but in a later stage, during an ongoing inflammatory 
process. A continuous stimulus of pro-inflammatory 
pathways will take place, triggering toll-like receptors 
(TLR) (NOD2 is a negative regulator of TLR signaling) 
and favoring Th1 response and the release of cytokines. 
Animal models have shown that NOD2 has a paramount 
importance in the bactericidal activity of ileal crypts 
and the regulation of ileal microbiota. This allows us to 
hypothesize that ileal CD caused by NOD2 mutations is 
due to the dysfunction of Paneth cells[8,10,21]. This diverse 
function of NOD2 may explain the heterogeneity of 
CD[16]. 
In what concerns CRC, there are several factors 
that could explain its link to NOD2 mutations. It is a 
well-known fact that the risk for CRC increases with 
duration and severity of the inflammatory process, 
while it decreases when anti-inflammatory drugs such 
as mesalazine and immunomodulators such as azathio-
prine are used in ulcerative colitis, consistent with a 
causative role for inflammation in colon carcinogenesis. 
The chemopreventive activity of aspirin and other 
nonsteroidal anti-inflammatory drugs in CRC supports 
this concept as well.
If these mutations play a consistent part in the 
pathogenesis of inflammatory bowel diseases (IBD), 
most notably in CD, then the hypothesis that such 
mutations are potential risk factors for cancer may 
have solid grounds. The study by Couturier-Maillard[9] 
shed some light in the role of NOD2 in colitis-associated 
cancer: NOD2-/- mice showed increased tumor load in 
the distal colon than wild-type animals. Furthermore, 
this risk was shown to be transmittable if both animals 
were cohoused. An acceptable rationale to explain these 
findings may involve an unbalance between pro- and 
anti-inflammatory cytokines and lead to the loss of 
autophagy and apoptosis stimuli. This could eventually 
lead to increased risk of infection, chronic inflammation 
and cancer[22]. 
The most promising body of evidence that supports 
the role of NOD2 in colorectal carcinogenesis involves its 
capacity to shape a protective assembly of gut bacterial 
communities. The deregulation of intestinal microbiota 
seems to be the essential element in the complex inter-
action between NOD2 mutations and CRC.
LINKING MICROBIOTA TO MUCOSAL 
IMMUNITY AND CRC
Recently, a significant effort has been made to identify 
the components and the role of intestinal microbiota 
in colonic health and homeostasis. The microbiota has 
been increasingly recognized as a major player in normal 
metabolic and physiologic processes. This community of 
1013-1014 microorganisms represents a perfect example 
of symbiotic relationship. It exerts several essential 
functions like the synthesis of essential compounds for 
the normal growth of colonic mucosa, regulation of its 
lymphoid tissue and synthesis of amino acids that inhibit 
the growth of pathogenic microorganisms. The latter is 
Branquinho D et al . NOD2 mutations and colorectal cancer
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of paramount importance, as a delicate equilibrium has 
to be achieved between commensal bacterial load and 
the innate immune system. The commensal bacteria 
must be contained in their capacity to proliferate and 
should be maintained in adequate amounts. Conversely, 
any change in the composition of luminal bacterial flora 
may favor the production of toxins and metabolites 
associated with carcinogenesis and induce dysregulation 
of the immune response, allowing pathogenic agents 
to replicate, therefore promoting and sustaining infla-
mmation and carcinogenesis[23]. A well balanced gut 
microbiota leads to healthy colocytes through the 
production of important compounds and the correct 
modulation of the immune system. It is now believed 
that NOD2 mutations may result in altered host-microbial 
interactions in the intestinal mucosa. 
COMPOSITION OF THE MICROBIOTA
It is known that the human intestine is sterile in utero, 
but progressively over 36000 bacterial species colonize 
the gastrointestinal tract and develop a symbiotic relation 
with their host. The human distal intestinal microbiota 
includes two predominant phyla, the Firmicutes and 
Bacteroidetes, with less significant contributions from 
Proteobacteria and Actinobacteria, and minor contributions 
from Fusobacteria, Verrucomicrobia, and Cyanobacteria[24]. 
The production of propionate and butyrate from the 
degradation of indigestible polysaccharides is one of its 
main roles. Despite being outnumbered by other species, 
Actinobacteria, Proteobacteria (including Escherichia coli) 
and Verrucomicrobia, showed potential to influence 
health outcomes[25]. A significant effort is being made 
to characterize the diverse genetic material of these 
numerous microorganisms (also known as microbiome). 
Ultimately, the goal is to understand the link between 
variations in the composition of these communities and 
common diseases, such as IBD and CRC. The hypothesis 
formulated by several investigators lies on the ability of 
these variations of the microbiota to cause a breakdown 
of the balance between bacterial communities and the 
epithelial barrier may lead to chronic inflammation. It is 
thought that some species may not be able to maintain a 
quiet state of protective immunity in dysbiotic conditions. 
For example, Bacteroides thetaiotaomicron was found 
to be not only a commensal but also an opportunistic 
microorganism in predisposed individuals[26]. 
A special attention has been devoted to factors 
that may influence the composition of the microbiota. 
Aging, place of birth and mode of delivery are quite 
relevant determinants. Antibiotics are also important and 
modifiable factors, especially with larger antimicrobial 
spectrums, as their effect on the microbiota varies 
from drastic to only temporary. After the end of the anti-
biotic treatment, certain species may recover in about 
a month while others may not recover at all, most 
often in children[27]. Besides antibiotics, different dietary 
habits may modify significantly the microbiota as well. 
Quite interestingly, even a short-term increase in fat 
and carbohydrate consumption may influence not only 
the relative abundance of each bacterial species, but 
also the functionality of the microbiota[28]. Obesity has 
also been proposed as a major factor in this equation, 
as it may alter the composition of the microbiota and 
increase its metabolic potential to harvest energy 
from the host diet. The capacity of the microbiota to 
confer host traits was revealed by studies where fecal 
content was transplanted from obese mice into lean 
germ-free recipients. The recipients showed significant 
weight gain and increased adiposity[29]. This surprising 
discovery opened the door for further investigation on 
genetic and microbiota manipulation and its ability to 
cause disease in animal models. Another interesting 
concept was revealed by Couturier-Maillard et al[9]. 
The absence of NOD2 confers a transmissible risk for 
colitis and CRC, even to immunocompetent hosts. In 
other words, after sharing the same environment with 
NOD2-/- mice, wild-type animals treated with dextran 
sodium sulfate revealed an increased risk for colitis, 
probably due to an altered commensal flora acquired 
from knockout mice. This dysbiotic microbiota is then 
passed to the next generation. Growing evidence now 
shows us that the risk for colitis and CRC is influenced 
by specific members of the commensal microbiota. In 
fact, in IL10-deficient mice treated with colon-specific 
carcinogen azoxymethane (AOM) showed high levels of 
mucosal inflammation and adenoma development when 
raised in conventional conditions, but when Bacteroides 
vulgatus is the only commensal, the carcinogenicity of 
AOM is somewhat attenuated. Even more surprising is 
the fact that these mice show almost no inflammation or 
adenomas if created in a germ-free environment[11]. This 
is consistent with the notion that treating NOD2-deficient 
mice with broad spectrum antibiotics may mitigate its 
disease risk[9]. In the opposite direction, a recent study 
suggests that antibiotics promote inflammation through 
translocation of commensal colonic bacteria and it is 
suggested that this may explain the association between 
increasing antibiotic use and the growing incidence of 
inflammatory disorders[30]. 
The importance of NOD2 as a regulator of microbiota 
and consequently as a risk factor for injury of the colonic 
mucosa was reinforced by studies using reciprocal fecal 
microbiota transplantation. Such interventions led to 
profound changes in the microbiota. The end result 
was that NOD2-deficient mice that received fecal trans-
plantation from wild-type animals showed decreased 
mucosal injury and inflammation. On the contrary, there 
was an increased risk of colonic disease in wild-type 
hosts that received dysbiotic fecal microbiota from NOD2-
deficient mice[9]. A crucial role in this equilibrium is played 
by Paneth cells, specialized secretory epithelial cells of 
the small intestinal crypts that express NOD2 at high 
levels. Recent studies demonstrated that NOD2-deficient 
mice had a significant rise in the amount of commensal 
bacteria in the terminal ileum, probably due to impaired 
cryptal activity[31]. This is a potential mechanism by which 
NOD2 mutations may disturb intestinal homeostasis and 
Branquinho D et al . NOD2 mutations and colorectal cancer
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lead to CD and colitis-associated CRC. But the intestinal 
microbiota role in this equilibrium is not passive at all. 
On the contrary, it is now known that it plays a part in 
controlling the expression of NOD2 as well. 
The influence of NOD2 in microbial communities 
and its consequences on disease risk have solid basis. 
But how exactly does an altered microbiota lead to 
colonic inflammation? One possible explanation is the 
production of bioproducts with anticancer properties by 
the metabolic machinery of the microbiota. Butyrate 
and other small-chain fatty acids are nutrients formed 
by the fermentation of indigestible carbohydrate and 
are known to have an interesting paradoxal activity. 
In colon carcinoma cells, it leads to apoptosis, inhibits 
cell proliferation and angiogenesis, therefore showing a 
protective effect. On the other hand, in normal colonic 
cells it shows opposite effects as it prevents apoptosis[32]. 
Another potential role for the microbiota and especially 
for butyrate is maintaining inhibition of the histone 
deacetylase, therefore maintaining histones in an 
acetylated state, thus facilitating the transcription of anti-
oncogenes[33]. This is an objective of anticancer drugs 
such as Vorinostat, an approved agent for the treatment 
of cutaneous T cell lymphoma. Detrimental influences are 
provided by the accumulation of toxic compounds in the 
gut that can exert a mutagenic action. Poli-heterocyclic 
amines, deoxycholic acid and calibactin are examples of 
compounds directly or indirectly produced by commensal 
bacteria that harbor potential to damage colonocytes’ 
DNA[34]. This conflicting evidence supports the idea 
that the role of the microbiota shouldn’t be considered 
univocal, but rather be regarded as a complex set of 
influences that may have a protective or deleterious 
effect on mucosal immunity, depending on its specific 
components. It is reasonable to postulate that the same 
bacterial agents will elicit different effects according to 
each individual genetic background and environmental 
exposure. 
CASE-CONTROL STUDIES ON NOD2 
POLYMORPHISMS
Conflicting
This is a common word found in the introduction of 
most studies on NOD2 mutations as a risk factor for 
CRC. However, for an adequate analysis of the pub-
lished results, several factors should be taken into 
consideration. 
First, the most studied polymorphisms of NOD2 have 
significantly different prevalence in different populations. 
Three of the most common polymorphisms were not 
found in 342 patients included in a Malaysian study[12]. 
On the contrary, in a Danish study that included more 
than 40000 individuals, about 13% were carriers of at 
least one of the polymorphisms[35]. An obvious conclusion 
is that we should analyze these results according to the 
geographic region where they were conducted. Even 
in European studies, where these polymorphisms are 
thought to be more common, the number of carriers 
is often low. For example, in a study from Finland, there 
was only one homozygote for the R702W mutation in a 
universe of 1400 subjects[36]. Achieving solid conclusions 
with such low numbers is extremely difficult. Another 
limiting aspect that may hinder the conclusions of 
such studies is the source of controls. The results differ 
according to the source of controls. According to a meta-
analysis that included 30 case-control studies about 
NOD2 polymorphisms and cancer risk[37], there was 
only an increased risk in the subgroup with hospital-
based controls, while no significant risk was observed 
in population-based studies. A factor worth looking at 
as well is that the great majority of studies about NOD2 
polymorphisms described so far analyzed only DNA 
extracted from nonneoplastic tissue (searching only 
germline mutations). For a complete understanding of the 
role of these mutations in the pathogenesis of CRC, an 
investigation of the neoplastic tissue should be undertaken 
as well (somatic mutations). To our knowledge, there is 
only one study that tried to determine if these mutations 
were of germline or somatic nature[38]. A total genotypic 
agreement between blood and neoplastic samples was 
observed, therefore suggesting that CRC susceptibility 
associated with these variants is linked to germline 
mutations, apparently without the participation of somatic 
mutations.
Most studies addressing NOD2 polymorphisms 
and CRC are essentially linkage studies concerning a 
specific country or region. Nowadays, genome-wide 
association studies (GWAS) have a significant impact 
on medical research. As they search for differences 
in allele frequencies or genotypes in a large number 
of patients, through the identification of thousands of 
single-nucleotide polymorphisms, GWAS have stronger 
statistical power than linkage studies. However, as 
it was already mentioned, the frequency of NOD2 
polymorphisms shows a significant geographic variability. 
As GWAS often recur to samples from a quite diverse 
set of countries, the effect of these polymorphisms in a 
certain population may go unnoticed. 
When analyzing the results from these studies, it is 
important to consider each polymorphism separately as 
well. It seems plausible to admit that each polymorphism 
will have different effects on NOD2 function and therefore 
its effect on cancer risk will probably be different as well. 
The most studied polymorphisms are two missense 
mutations - rs2066845 C/G (G908R) and rs2066844 C/T 
(R702W), and one frameshift mutation - rs2066847 insC 
(3020insC). For the first missense mutation, G908R, 
results are equivocal (Table 1). Case-control studies failed 
to identify an increased susceptibility to CRC for G908R 
mutation carriers in German, Portuguese and Hungarian 
populations[13,38,39]. On the other hand, a Greek study 
was able to find an association between this mutation 
and CRC susceptibility[40]. In what concerns meta-
analysis, the results are conflicting. In the meta-analysis 
by Tian et al[41], there is evidence for an increased 
risk, but more recently, in 2014, a new meta-analysis 
showed no association between CRC and the G908R 
mutation[37]. For the last of the missense mutations, 
Branquinho D et al . NOD2 mutations and colorectal cancer
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R702W, there is strong evidence for an important role 
in CRC susceptibility. Several population-based studies 
and two meta-analyses revealed a significantly increased 
prevalence of this mutation in CRC patients (Table 1). For 
the frameshift mutation 3020insC, most studies support 
a relevant role for an increased risk of disease (Table 1)[40,42]. 
Both meta-analysis published on this subject revealed 
that carrying the 3020insC mutation was associated with 
a higher risk for CRC development[37,41]. 
If our objective is to assess the risk for CRC in 
NOD2 polymorphism carriers, we should analyze the 
combined effect of the three main mutations. Several 
studies tried to determine if there was an increased 
risk for an individual carrying at least one of these 
polymorphisms. According to at least three population-
based studies[13,38,40], there was evidence of an increased 
CRC risk if one or more of the described polymorphisms 
were identified.   
Besides searching for a potential role for NOD2 
mutations and a hypothetic increased susceptibility for 
CRC, several groups searched for genotype-phenotype 
correlations in these patients. One of the main concerns 
for investigators and clinicians working in the field of 
CRC are young patients suffering from this disease. 
Finding a marker of increased risk that could identify 
patients under 50 that should enter an early surveillance 
program is obviously a sought-after goal. In a German 
cohort of patients under 50, a significant association 
between NOD2 mutations and CRC susceptibility was 
described[13]. In a Portuguese study[38], the R702W 
variant was associated with an increased risk for CRC 
only in female patients under 60. In the opposite 
direction, the groundbreaking work by Kurzawski et al[42], 
the first group that tried to find a correlation between 
these polymorphisms and CRC, revealed a bigger pro-
pensity of 3020insC mutation carriers to develop CRC 
at a later age. An association with certain phenotypic 
characteristics was researched as well. Tumor location 
and size, vascular or lymphatic invasion, differentiation 
and distance to margins in resected specimens showed 
no relation with the presence of NOD2 polymorphisms 
in most studies[38,39,43]. This lack of genotype-phenotype 
agreement may be due to the genetic heterogeneity of 
the disease or it can be explained by the small number of 
mutation carriers diagnosed with CRC, therefore limiting 
the ability to reach such a conclusion. Only a Greek study 
was able to show a relevant association between tumor 
stage (TNM classification) and the occurrence of these 
mutations[40].
Currently, new therapies for cancer are designed for 
a specific set of patients that are expected to respond, 
according to certain clinical and biological features. For 
example, Cetuximab is only prescribed to patients with 
advanced CRC and no mutation in the KRAS gene (wild 
type at codons 12 and 13 of KRAS). For NOD2 mutations, 
a potential role for predicting response to treatment 
was researched as well. In 2014, Omrane et al[44] des-
cribed an association between CRC patients carrying 
3020insC polymorphism and the need for neoadjuvant 
chemotherapy. The presence of this polymorphism was 
able to predict failure of neoadjuvant chemotherapy. 
Conversely, the presence of 3020insC mutation was pre-
dictive of successful adjuvant chemotherapy[44]. Despite 
the relatively small size of the sample, this may be a 
promising role for NOD2 mutations, needing confirmation 
by large-scale studies. 
Routine detection of NOD2 mutations is still not being 
offered in the management of CRC patients. However, 
there is a new simple and cost-effective tool for the genetic 
screening of CRC[45]. Besides well-known mutations in 
MLH1, MSH2 and MSH6 genes, the DNA microarray 
assay also searches the 3020insC polymorphisms in the 
NOD2 gene. This may be a useful tool in clinical practice 
in CRC screening programs.
Due to the already described conflicting nature of the 
results from studies on NOD2 mutations and CRC risk, 
Country Finland[36] Greece[40] Hungary[39] New Zealand[43] Portugal[38]
CRC (n) 953/960/9261 104 194 133 112
Controls (n) 508/508/3481 100 200 201 152
R702W
   CRC % Allele frequency 2.2        4.8        1.8        7.1      12.5
   Control % Allele frequency 2.1        1.0        1.5        3.0        5.3
P value   0.88          0.02          0.78          0.03          0.03
G908R
   CRC % Allele frequency 0.3          8.65        1.8        2.2          2.73
   Control % Allele frequency 0.2        3.5        1.8        0.8          3.29
P value   0.57            0.025          0.95          0.09          0.77
3020insC
   CRC % Allele frequency 1.9      12.5        3.6        2.2          0.89
   Control % Allele frequency 1.9     6        2.5        1.0        1.3
P value   0.96            0.017          0.40          0.19          0.75
At least one mutation
   CRC % Genotype frequency -      51.9      14.4      21.8      16.1
   Control % Genotype frequency -      21.0      11.5        8.9        9.9
P value -          < 0.0001          0.45            0.001            0.132
Table 1  Genotype frequencies of the nucleotide-binding and oligomerization-domain containing 2 polymorphisms
1CRC cases and controls for each mutation, respectively (R702W, G908R, 3020insC). CRC: Colorectal cancer. 
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two meta-analyses on this subject were conducted (Table 
2)[37,41]. The first was published in 2010 and remains, to 
our knowledge, the only meta-analysis that studied NOD2 
mutations and CRC exclusively. A total of 85 papers 
were screened, but only 8 were considered appropriate 
to be included (all from Caucasian populations), totaling 
3524 CRC cases and 2364 controls (Table 2). The most 
significant risk for CRC was found in patients carrying 
the G908R mutation (5 studies; OR = 1.98; 95%CI: 
1.14-3.44). Increased risk was also found for the R702W 
mutation (5 studies; OR = 1.59; 95%CI: 1.09-2.32) 
and the missense mutation 3020insC (7 studies; OR 
= 1.44; 95%CI: 1.13-1.84). For an individual carrying 
at least one of these high-risk alleles, there is also an 
increased probability of developing CRC (5 studies; OR 
= 1.58; 95%CI: 1.03-2.42). The most recent meta-
analysis on this subject studied the effect of NOD2 
mutations in the susceptibility for several types of cancer 
(melanoma, breast cancer, non-Hodgkin lymphoma 
and different gastrointestinal tumors). A total of 30 
articles were included, 11 of which exclusively with CRC 
patients, published from 2004 to 2010. The results were 
similar to the ones described by Tian et al[41], as it was 
demonstrated that both R702W and 3020insC were risk 
factors for CRC (Table 2). The only discrepancy was the 
effect of carrying G908R polymorphism. This allele was 
found to contribute to the overall risk of cancer, but not 
specifically to CRC. The studies included in this meta-
analysis showed no obvious heterogeneity (I2 < 50%). 
Excluding any of the included studies would not change 
significantly the outcome, therefore suggesting that 
these results are statistically robust[41].
NOD2 MUTATIONS AND OTHER 
MALIGNANT AND NON-MALIGNANT 
CONDITIONS
Since the publication in 2001 by Ogura et al[4] of the first 
study about NOD2 mutations and increased susceptibility 
to CD, several investigators tried to understand the 
intricate mechanism behind this association and to find 
a link between these polymorphisms and other inflam-
matory and malignant conditions. 
In fact, a role for NOD2 mutations has been pos-
tulated for several malignant diseases other than CRC. In 
common digestive tract tumors, a significant number of 
published studies have addressed this putative relation. 
The 3020insC missense mutation was shown to be a risk 
factor for intestinal type gastric cancer in a Portuguese 
population[46]. The same was demonstrated by an Italian 
study for the R702W and 1007fs polymorphisms[47]. 
According to the meta-analysis by Liu et al[37], there 
was an increased risk for gastric cancer for carriers 
of the G908R and 3020insC mutations, but the same 
was not observed for the R702W polymorphism. In a 
recent population-based Chinese study, an increased 
risk for gastric cancer was found for individuals carrying 
the rs718226 AG or GG genotype. Interestingly, this 
single-nucleotide polymorphism revealed significant joint 
effects with H. pylori in dysplasia and gastric cancer risk. 
On the contrary, both the rs2111235 C allele and the 
rs7205423 G allele showed a protective effect, as they 
were associated with a decreased risk of progression 
to dysplasia and gastric cancer in H. pylori-infected 
subjects[48].
In what concerns pancreatic cancer, there was no 
evidence of increased risk neither in the familial nor 
the sporadic form of the disease[37,49]. The same meta-
analysis revealed an increased risk for MALT lymphoma, 
breast, lung and laryngeal cancer for the carriers of the 
3020insC mutation. On the other hand, none of the NOD2 
mutations were found to be risk factors for melanoma or 
non-Hodgkin lymphoma[37]. 
These discrepancies found between different studies 
may be attributed to a variety of factors, especially those 
that influence the expression of these polymorphisms, as 
well as differences in sample size, geographic variation or 
genotyping methods[22].
Branquinho D et al . NOD2 mutations and colorectal cancer
Meta-analysis Liu et al [37] (2014) Tian et al [41] (2010)
R702W
   Variant genotypes vs homozygous wild-type OR   1.32 1.59
95%CI 1.01-1.72 1.09-2.32
P value   0.04 0.02
G908R
   Variant genotypes vs homozygous wild-type OR   1.32 1.98
95%CI 1.01-1.72 1.14-3.44
P value 0.04 0.01
3020insC
   Variant genotypes vs homozygous wild-type OR   1.23 1.44
95%CI 1.10-1.38 1.13-1.84
P value < 0.001   0.003
R702W/G908R/3020insC
   Variant genotypes vs homozygous wild-type OR - 1.58
95%CI - 1.03-2.42
P value - 0.03
Table 2  Nucleotide-binding and oligomerization-domain containing 2 polymorphisms and 
cancer risk: Results of meta-analysis
OR: Odds ratio.
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The effect of NOD2 as a risk factor for disease is best 
established in CD. After an etiologic role was consolidated 
for these mutations in CD, further investigation was 
undertaken to find out if these mutations influenced 
the behavior, prognosis and response to treatment as 
well. The presence of one mutation increased the risk 
for structuring or penetrating disease by 8% and this 
effect was largely increased if two NOD2 mutations were 
present (41% risk increase)[38]. An Australian study 
revealed as well that carriers have a more aggressive 
disease, needing more frequent and more precocious 
surgery[50]. A recent European multicenter cohort study 
recently revealed that NOD2 mutations and early use 
of immunomodulatory drugs are the most relevant 
predictors of the course of disease[51]. 
It was speculated as well that certain disease 
phenotypes and their response to treatment could be 
influenced by NOD2 mutations. The development of 
perianal fistulas is thought to depend on the proliferation 
of luminal bacteria. As such a possible connection 
between NOD2, a regulator of host response to microbial 
agents, and perianal fistulas was evaluated in recent 
literature. These fistulas showed significantly worse 
response to antibiotics in NOD2 mutation carriers[52], 
probably due to impaired recognition of intestinal bacteria 
and a decreased ability to mount an effective innate 
immune response. This kind of studies emphasizes the 
importance of gene mapping and corresponding pheno-
typic correlations in order to predict disease severity and 
optimize treatment strategies. 
CONCLUSION
In the last fifteen years, the proposed role of NOD2 and 
its mutations in disease has grown significantly. From 
only a susceptibility gene to an important predictor 
of prognosis and response to treatment in CD, these 
mutations have been postulated as a risk factor in several 
conditions such as mycobacterial infections, common 
gastroenterological disorders and malignant diseases like 
gastric and colorectal cancer. The expanding role of this 
receptor as a major coordinator of several inflammatory 
pathways and a modulator of microbiota is increasingly 
accepted, mainly due to evidence arising from NOD2-
deficient animal models. In fact, it was shown that losing 
NOD2 activity leads to more severe colitis and higher 
propensity to adenomas and CRC. It seems likely that 
NOD2 may be the key element of the intricate puzzle 
that links the disturbance of mucosal immune defense, 
dysbiotic bacterial communities and conditions such as 
CD and colitis-associated CRC. 
Furthermore, NOD2 polymorphisms such as 3020insC 
and R702W seem to increase susceptibility to CRC. The 
search of these mutations is still not offered routinely in 
clinical practice. However, the identification of its carriers 
would allow such patients to be included in a more 
intense CRC surveillance program, contributing to early 
diagnosis of a disease that carries such a heavy burden. 
Predicting response to different chemotherapy regimens 
according to the presence of NOD2 polymorphisms could 
become a useful tool for clinicians. More large-scale 
studies should be conducted to confirm this association. 
The development of new therapeutic targets based on 
research about NOD2 protein function and interactions 
could ultimately lead to a tailored approach to the 
treatment of CRC.
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